Bioarctic is a long-term growth investment into a bio-tech research company developing Alzheimer medication and other nervous system related medication. Its leading product LEQEMBI is a fast growing Alzheimer disease modification treatment.
LEQEMBI sales are expected to turn BioArctic profitable in 2025. The company is valued at 14x PS 2025 and around 17x PE 2026. BioArctic is the market leader in AD, and has a portfolio with nervous system related treatments. I expect the price to recover above 200 in 2024 upon EU approval (after the recent 35% drop). In the longer term the share price has the potential to double (3-5 years).